CompletedPhase 1NCT00858429
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Studying Rare tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Mary Mulcahy, MDRobert H. Lurie Cancer Center
- Intervention
- capecitabine(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2009 – 2014
Study locations (1)
- Northwestern University, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00858429 on ClinicalTrials.govOther trials for Rare tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07356531Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver CancerJIANGSU SHENMING Medical Technology CO., Ltd
- ACTIVE NOT RECRUITINGNCT04145141National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT02984566Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)University of Sydney
See all trials for Rare tumor of liver and intrahepatic biliary tract →